FY2024 EPS Estimates for Gilead Sciences Lifted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Zacks Research lifted their FY2024 earnings per share estimates for shares of Gilead Sciences in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will post earnings of $4.26 per share for the year, up from their previous estimate of $3.73. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.37 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2024 earnings at $1.55 EPS, Q1 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.87 EPS, Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $6.91 EPS, Q1 2026 earnings at $1.55 EPS, Q2 2026 earnings at $1.75 EPS and FY2026 earnings at $7.44 EPS.

Several other equities research analysts have also recently commented on GILD. Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Cantor Fitzgerald raised their price target on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Wolfe Research initiated coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Finally, Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Gilead Sciences Stock Up 1.0 %

NASDAQ GILD opened at $91.35 on Monday. The stock has a fifty day moving average of $87.74 and a 200-day moving average of $77.31. The stock has a market capitalization of $113.85 billion, a P/E ratio of 1,015.00, a price-to-earnings-growth ratio of 2.80 and a beta of 0.17. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 EPS.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently modified their holdings of the business. Tri Ri Asset Management Corp bought a new stake in shares of Gilead Sciences in the third quarter valued at about $3,380,000. Synovus Financial Corp boosted its position in shares of Gilead Sciences by 99.6% in the third quarter. Synovus Financial Corp now owns 37,265 shares of the biopharmaceutical company’s stock valued at $3,124,000 after acquiring an additional 18,592 shares during the period. Tidal Investments LLC boosted its position in shares of Gilead Sciences by 9.9% in the third quarter. Tidal Investments LLC now owns 111,464 shares of the biopharmaceutical company’s stock valued at $9,345,000 after acquiring an additional 10,078 shares during the period. Optimist Retirement Group LLC boosted its position in shares of Gilead Sciences by 5.4% in the third quarter. Optimist Retirement Group LLC now owns 27,234 shares of the biopharmaceutical company’s stock valued at $2,283,000 after acquiring an additional 1,391 shares during the period. Finally, Blankinship & Foster LLC bought a new stake in shares of Gilead Sciences in the third quarter valued at about $1,006,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,947 shares of company stock worth $4,968,674. Insiders own 0.16% of the company’s stock.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.37%. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.